A 92% response rate in a disease as lethal as pancreatic cancer
For decades, a diagnosis of pancreatic cancer has carried with it a quiet finality — a disease that outpaces nearly every treatment medicine has offered it. In early June 2026, two biotech companies reported something that rarely enters this particular conversation: a 92 percent response rate in patients whose tumors carried a specific genetic signature, achieved by pairing two experimental drugs in an early-stage trial. The result does not yet rewrite the standard of care, but it opens a door that, for a genetically defined subset of patients, has long appeared sealed.
- Pancreatic cancer kills most patients within a year of diagnosis, and standard treatments succeed only 20 to 40 percent of the time — making a 92% response rate not just notable but almost disorienting in its scale.
- The combination of vopimetostat and daraxonrasib targeted patients whose tumors carried both MTAP deletion and RAS mutation, exploiting the precise genetic vulnerabilities that make these cancers so aggressive.
- Tango Therapeutics' stock surged 53% in a single day, a market signal that even seasoned investors recognized this as the kind of data that almost never emerges from early oncology trials.
- The results come from an early-stage trial — rigorous enough to signal promise, but not yet large enough to prove survival benefit or displace existing treatment protocols.
- Larger Phase 2 trials must now confirm whether tumors that respond also translate into longer lives, keeping this breakthrough in the realm of profound hope rather than established medicine.
Pancreatic cancer has long resisted medicine's best efforts — a disease that kills most patients within a year, shrugs off chemotherapy, and offers little room for optimism. That context makes the announcement from Tango Therapeutics and Revolution Medicines in early June 2026 all the more striking: their experimental drug combination produced a 92 percent response rate in patients with a specific genetic subtype of the disease.
The two drugs — vopimetostat and daraxonrasib — were tested together in patients whose pancreatic tumors had lost the MTAP gene and carried RAS mutations. In this population, tumors shrank or disappeared in 92 out of every 100 patients treated. Standard pancreatic cancer regimens typically achieve response rates between 20 and 40 percent. The gap is not incremental — it is categorical.
The financial markets responded immediately. Tango's stock climbed 53 percent in a single session, a number that reflected what oncologists were already saying in quieter rooms: results like this almost never happen in this disease. The drugs work through distinct but complementary mechanisms — vopimetostat inhibits a protein called LSD1, while daraxonrasib targets a separate pathway — and together they appear to overwhelm defenses that have historically made pancreatic tumors so difficult to treat.
The caution appropriate to early-stage data remains. These trials are designed to establish safety and initial efficacy, not to prove superiority over existing treatments in large populations. Tango and Revolution must now advance into Phase 2 studies, tracking not just tumor response but whether patients live longer and maintain their quality of life. The regulatory road is long. But for patients carrying MTAP-deleted, RAS-mutant tumors — a group that has had almost nowhere to turn — this moment offers something genuinely rare: a credible reason to believe the next chapter of their disease might be written differently.
Pancreatic cancer has long been one of the cruelest diagnoses in oncology—a disease that kills most of its patients within a year of diagnosis, that resists conventional chemotherapy, that offers little room for hope. But in early June, two biotech companies announced results that broke that pattern in a meaningful way: a combination of two experimental drugs produced a 92% response rate in patients whose tumors carried specific genetic mutations.
The drugs are vopimetostat, developed by Tango Therapeutics, and daraxonrasib, from Revolution Medicines. Together, they were tested in patients with pancreatic cancer that had lost the MTAP gene and carried mutations in the RAS gene—a genetic profile that defines a subset of pancreatic tumors. In this population, the combination caused tumors to shrink or disappear in 92 out of every 100 patients who received it. For context, standard pancreatic cancer treatments typically produce response rates in the 20 to 40 percent range.
The announcement sent Tango's stock soaring 53 percent in a single day, a visceral measure of how rare and unexpected this kind of result is in cancer drug development. The financial markets were reading what the oncology community was saying: this looked unprecedented. The data came from an early-stage trial, the kind designed primarily to test whether a drug is safe and whether it works at all, not to prove it works better than existing treatments in a large population. But even accounting for that limitation, a 92 percent response rate in a disease as lethal as pancreatic cancer is the kind of number that stops conversations in hospital corridors.
What makes this finding particularly significant is that it targets a genetically defined patient population. The MTAP-deleted, RAS-mutant subtype represents a meaningful fraction of pancreatic cancer cases—patients who, until now, had few options beyond standard chemotherapy regimens that often failed them. By identifying the specific genetic vulnerabilities in their tumors, the two drugs exploit pathways that cancer cells in this group depend on. Vopimetostat works by inhibiting a protein called LSD1; daraxonrasib targets a different mechanism. Together, they appear to create a combination potent enough to overcome the tumor's defenses.
The path forward is now measured and deliberate. Early-stage trial results, no matter how striking, must be validated in larger, more rigorous studies before they can reshape clinical practice. Tango and Revolution will need to move into Phase 2 trials, enrolling more patients, tracking not just whether tumors respond but whether patients live longer and maintain quality of life. The regulatory pathway to approval remains long. But for patients with MTAP-deleted, RAS-mutant pancreatic cancer—a group that has historically had almost nowhere to turn—this announcement represents something that has been scarce in their disease: a genuine opening, a reason to believe that the next generation of treatment might be different.
Notable Quotes
The data was described as unprecedented by observers in the oncology field— Industry analysts and medical commentators
The Hearth Conversation Another angle on the story
Why does a 92% response rate matter so much if this is just an early trial? Aren't early trials always optimistic?
They are, and that's the right skepticism. But 92% is not just optimistic—it's a signal that something fundamental might be different about how these two drugs work together in this specific genetic context. Standard pancreatic cancer drugs get 20 to 40 percent responses. You don't see jumps like this unless the biology is aligned.
So the genetic mutations—MTAP-deleted and RAS-mutant—those are like a lock, and these drugs are the key?
Exactly. Most pancreatic cancers are genetically messy, hard to target. But this subtype has specific vulnerabilities. The drugs exploit those vulnerabilities. It's precision medicine working the way it's supposed to.
What happens to patients whose tumors don't respond? That's still 8 out of 100.
That's the hard part nobody talks about much. We don't know yet why some patients respond and others don't. That's what the next trials will try to figure out. But even if the 92% holds up, those 8 percent are still facing a disease with few alternatives.
How long until this is actually available to patients?
Years, probably. Phase 2 trials, then Phase 3, then regulatory review. If everything goes well, maybe three to five years. The stock market is pricing in success, but the actual path is slower and less certain.
And if it works in the larger trials?
Then pancreatic cancer treatment changes for this patient population. Not a cure, but a real option where there wasn't one before. That's significant.